Pulmonary Hypertension Drugs Market is driven by Rising Disease...

adicionou um novo artigo Health

2025-05-27 11:30:04 -

Pulmonary Hypertension Drugs Market is driven by Rising Disease Prevalence

Pulmonary hypertension drugs encompass a diverse portfolio of therapeutic agents designed to lower pulmonary arterial pressure, improve right ventricular function and enhance patient quality of life. Key classes include endothelin receptor antagonists (ERAs), phosphodiesterase type 5 (PDE-5) inhibitors, prostacyclin analogs and soluble guanylate cyclase (sGC) stimulators. These products offer...

0 Comentários 0 Compartilhamentos 512 Visualizações 0 Anterior